Switch to
More onapp

How to use scorecard? Learn more

GlaxoSmithKline Pharmaceuticals Ltd

GLAXO
Health CarePharmaceuticals
MidcapWith a market cap of ₹39,447 cr, stock is ranked 223
Moderate RiskStock is 2.55x as volatile as Nifty
2,304.1042.70 (-1.82%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹39,447 cr, stock is ranked 223
Moderate RiskStock is 2.55x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
58.44
PB RatioPB Ratio
22.19
Dividend YieldDiv. Yield
1.37%
Sector PESector PE
51.53
Sector PBSector PB
6.56
Sector Div YldSctr Div Yld
0.52%

Forecast & RatingsDetailed Forecast 

50%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

GlaxoSmithKline Pharmaceuticals is a pharmaceutical company engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in pharmaceuticals, vaccines and consumer healthcare.

Brands

Glaxosmithkline Pharma

Pharmaceutical company

Brands

Glaxosmithkline Pharma

Pharmaceutical company

Financial TrendFinancial statements 

20212022202320243.144.703.373.600.361.690.610.59
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Clarification - Financial Results 
Announced OnDec 4, 2024
The Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. -2. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
The Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. -2. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
General Updates 
Announced OnNov 27, 2024

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about General Updates | Download

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about General Updates | Download

Cash Dividend 
Ex. DateNov 7, 2024

Special • Div/Share: ₹ 12

See all events